Clinical scenario: An otherwise healthy 25-year-old woman returns to your office for management of chronic primary immune thrombocytopenia. She was diagnosed 6 months earlier and continues to require prednisone 15 mg daily and periodic infusions of intravenous immunoglobulin to maintain a hemostatic platelet count. You discuss second-line treatment options, including splenectomy. The patient asks if there are any means by which to predict likelihood of response to splenectomy. You have heard about the use of indium-labeled autologous platelet scanning for this purpose and wonder what the evidence shows.

Immune thrombocytopenia (ITP) comprises a heterogeneous group of disorders characterized by autoimmune-mediated platelet destruction by tissue macrophages in the spleen and elsewhere, variable impairment of thrombopoiesis, and an elevated risk of bleeding. Splenectomy remains a highly effective and well-tolerated treatment for patients refractory to or intolerant of first-line therapy with long-term complete response rates of 66%.1–3  Nevertheless, splenectomy is not without its drawbacks, including complications related to surgery and anesthesia in the short-term and lifelong risks of serious infection and possibly thromboembolism.2 

Indium-labeled autologous platelet scanning (ILAPS) is a nuclear imaging modality in which autologous platelets are reinfused into the patient after ex vivo labeling with 111In. Subsequent scintigraphy demonstrates the site(s) of platelet sequestration and clearance. It has been proposed that patients with purely or predominantly splenic sequestration determined by ILAPS may be more likely to respond to splenectomy than those exhibiting hepatic, mixed, or diffuse patterns.4  To evaluate the potential of ILAPS to predict response to splenectomy, we performed a comprehensive literature review of all studies in which ILAPS was performed prior to splenectomy in patients with ITP.

A search of the PubMed database limited to English language references was conducted by combining the MeSH (Medical Subject Heading) term “indium” with the keywords “ITP,” “immune thrombocytopenic purpura,” “idiopathic thrombocytopenic purpura,” and “autoimmune thrombocytopenia” between 1950 and June 30, 2010. This strategy yielded 51 citations. Excluded were 32 studies in which either ILAPS or splenectomy was not performed, 6 case reports, and 3 reviews. Of the 10 remaining references, 1 did not include data on response to splenectomy, 1 did not provide information on the sequestration pattern observed with ILAPS, and 3 were preliminary reports of ongoing case series for which updated iterations have been published, leaving 5 eligible studies.5–9  A search of abstracts from the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the European Haematology Association since 2003 identified a sixth eligible study (n = 580 for all eligible studies). A manuscript describing this study was in press at the time of our literature search and was graciously provided by the authors for inclusion in the present analysis.10 

In a pooled analysis of the six eligible studies (Table 1), patients with a splenic or predominantly splenic pattern of platelet sequestration by ILAPS demonstrated a higher response rate following splenectomy than those with a hepatic, diffuse, or mixed pattern (0.914 vs 0.409; odds ratio 15.4; 95% CI 9.6–24.8). The validity of this analysis is limited by differences among the six studies with respect to the study population, definition of response, timing of assessment for response, and ILAPS methodology and interpretation. Nonetheless, we conclude that ILAPS holds promise as a tool for predicting response to splenectomy in patients with chronic ITP. Additional prospective studies utilizing well-defined patient populations, recommended definitions of response,11  and standardized methods for ILAPS12  are needed to confirm the value of this procedure. Until higher level evidence is available, we do not recommend the routine use of ILAPS for predicting response to splenectomy in centers without extensive experience with this modality (grade 2C).13 

Conflict-of-interest disclosure: D.B.C. has consulted for Glaxo-Smith-Kline and Amgen. A.C. declares no competing financial interests.

Off-label drug use: None disclosed.

Adam Cuker, MD, MS, Penn Comprehensive Hemophilia and Thrombosis Program, Hospital of the University of Pennsylvania, 3 Dulles, 3400 Spruce St., Philadelphia, PA 19104; Phone: (215) 615-6555; Fax: (215) 615-6599; e-mail adam.cuker@uphs.upenn.edu

1
Schwartz
J
Leber
MD
Gillis
S
et al
Long-term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP)
Am J Hematol
2003
72
94
98
2
Kojouri
K
Vesely
SK
Terrell
DR
George
JN
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications
Blood
2004
104
2623
2634
3
Vianelli
N
Galli
M
de Vivo
A
et al
Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases
Haematologica
2005
90
72
77
4
Peters
AM
Saverymuttu
SH
Wonke
B
Lewis
SM
Lavender
JP
The interpretation of platelet kinetic studies for the identification of sites of abnormal platelet destruction
Br J Haematol
1984
57
637
649
5
Cola
B
Tonielli
E
Sacco
S
Brulatti
M
Franchini
A
Surgical treatment of chronic idiopathic thrombocytopenic purpura
Int Surg
1986
71
195
198
6
Siegel
RS
Rae
JL
Barth
S
et al
Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura
Am J Hematol
1989
30
206
212
7
Lamy
T
Moisan
A
Dauriac
C
Ghandour
C
Morice
P
Le Prise
PY
Splenectomy in idiopathic thrombocytopenic purpura: its correlation with the sequestration of autologous indium-111-labeled platelets
J Nucl Med
1993
34
182
186
8
Najean
Y
Rain
JD
Billotey
C
The site of destruction of autologous 111In-labeled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies
Br J Haematol
1997
97
547
550
9
Louwes
H
Zeinali Lathori
OA
Vallenga
E
de Wolf
JT
Platelet kinetic studies in patents with idiopathic thrombocytopenic purpura
Am J Med
1999
106
430
434
10
Sarpatwari
A
Provan
D
Erquo
S
Sobnack
R
Tai
FWD
Newland
AC
Autologous 111In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry
Br J Haematol
2010
10
18
[Epub ahead of print]
11
Rodeghiero
F
Stasi
R
Gernsheimer
T
et al
Standardization of terminology, definitions, and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Blood
2009
113
2386
2393
12
[No authors listed.] Recommended method for indium-111 platelet survival studies. International committee for standardization in hematology. Panel on diagnostic applications of radionuclides
J Nucl Med
1988
29
564
566
13
Guyatt
GH
Cook
DJ
Jaeschke
R
Pauker
SG
Schunemann
HJ
Grades of recommendation for antithrombotic agents: American Collge of Chest Physicians evidence-based clinical practice guidelines (8th edition)
Chest
2008
133
6 Suppl
123S
131S